Skip to contentL
Ligand Pharmaceuticals Inc
L
LGNDLigand Pharmaceuticals Inc Source filing unavailable
Q4 2011 · —
derived · Computed from the longer spans the company filed.
Revenue$13.64M$13.64Mderived+5.4% vs Q4 2010 Net Income$1.06M$1.06Mderived−77.3% vs Q4 2010 EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived$4,272,000−8.4% The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ligand Pharmaceuticals Inc · CIK 886163 · Engraved from SEC EDGAR
Margins · derivedOperating margin31.3%−4.7 pt vs Q4 2010
Net margin7.8%−28.5 pt vs Q4 2010